Table 1.

Patient characteristics.

All patientsn = 53ARM 1 (DD)n = 25ARM 2 (MN)n = 28
Median age, years (range)52.3 (20.9–76.4)50.8 (21.3–75.9)55.5 (20.9–76.4)
Female/male13/406/197/21
Median KPS (range)90 (70–100)90 (70–100)90 (70–100)
Tumor type at screeninga
Glioblastoma, IDH wildtype351619
Glioblastoma, IDH mutant404
Glioblastoma, NOS110
Anaplastic astrocytoma, IDH mutant963
Anaplastic astrocytoma, IDH wildtype220
Diffuse midline glioma, H3K27M mutant202
1st/2nd recurrence
1st relapse381820
2nd relapse1578
IDH mutation statusb
IDH mutant1367
IDH wildtype391821
MGMT promoter statusc
Methylated241014
Unmethylated281414
Prior brain tumor therapies
Concurrent XRT/TMZ followed by adjuvant TMZ502327
XRT and TMZ in sequential321
Othersd18108
  • Abbreviations: AA, anaplastic astrocytoma; DD, dose-dense; GBM, glioblastoma; IDH, isocitrate dehydrogenase; KPS, Karnofsky performance status; MN, metronomic; NOS, not otherwise specified; TMZ, temozolomide; XRT, radiation therapy.

  • aTumor type at screening is based on “The 2016 World Health Organization Classification of the Tumor of the Central Nervous System.”

  • bIDH mutation status is not available in 1 patient due to lack of enough tumor material.

  • cMGMT promoter methylation status is not available due to lack of enough tumor material in 1 case.

  • dOther therapies include clinical trial therapies, reirradiation, TTF (Tumor Treating Field). All 18 patients who received these therapies also received concurrent XRT/TMZ followed by adjuvant TMZ as well.